NAGE Niagen Bioscience Inc
Healthcare$3.90+0.00%OpenMarket Cap: $310.2M
As of 2026-05-26
Valuation
P/E (TTM)
20.59
PEG
0.20
P/B
3.55
P/S
2.24
EV/EBITDA
17.02
DCF Value
$-1.76
FCF Yield
1.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
8.5%
Net Margin
14.3%
ROE
25.4%
ROA
16.3%
ROIC
11.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $31.5M | 63.5% | $1.6M | $6.3M | $— | — |
| Q4 null | $33.8M | 64.1% | $2.1M | $4.1M | $— | — |
| FY null | $129.4M | 64.3% | $14.3M | $17.4M | $— | — |
| Q3 null | $34.0M | 64.5% | $4.2M | $4.6M | $— | — |
| Q2 null | $31.1M | 65.0% | $3.2M | $3.6M | $— | — |
| Q1 null | $30.5M | 63.4% | $4.8M | $5.1M | $— | — |
| Q4 null | $29.1M | 62.5% | $7.1M | $7.2M | $— | — |
| FY null | $99.6M | 61.8% | $7.7M | $8.6M | $— | — |
| Q3 null | $25.6M | 63.5% | $1.6M | $1.9M | $— | — |
| Q2 null | $22.7M | 60.2% | $-256.0K | $-15.0K | $— | — |
| Q1 null | $22.2M | 60.7% | $-731.0K | $-492.0K | $— | — |
| Q4 2023 | $21.2M | 61.0% | $-168.0K | $114.0K | $0.00 | — |